A meta-analysis of the efficacy and safety of human serum albumin treatment in patients with ascites due to cirrhosis undergoing drainage

摘要

Ascites is the most common complications of liver cirrhosis. 1 Meanwhile, Cirrhotic patients with portal hypertension severe enough to cause ascites usually have hypoproteinemia. Albumin is a protein synthesized by the liver, and among its many properties is its value in maintaining colloidal osmotic pressure. This charac- teristic has been used therapeutically in patients with ascites. 2,3 However, the choice of human serum albumin (HSA) treatment or albumin substitute (AS) in the treatment of these patients remains controversial. So, the published literature was systematically reviewed, and a meta-analysis was performed, comparing the effi- cacy and safety of HSA to AS in the treatment of cirrhotic patients with ascites undergoing paracentesis drainage.